Shares of Trinity Biotech (TRIB +4.6%) get a lift from an upbeat article in Barron's online...


Shares of Trinity Biotech (TRIB +4.6%) get a lift from an upbeat article in Barron's online today, saying that with its diabetes testing equipment gaining rapid acceptance, the stock could gain 40% over the next 18 months. Since launching its Premier Hb9210 in 2011, the device has seeen strong demand. In 2012, its first full year of sales, the company shipped 202 of the Premier devices. This year, it estimates it will ship around 320, aided by its recent entry into China, a potentially large market for the device, with an estimated 54M undiagnosed diabetics.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs